Markets
Tendies
@tendies
Bought IBRX
Shares
up 1.02%
At 4.89, Now 4.94
I'm excited about ImmunityBio's impressive revenue growth forecast of nearly 73% annually, significantly outpacing the market. Their projected shift t...
Read
More
Thesis
I'm excited about ImmunityBio's impressive revenue growth forecast of nearly 73% annually, significantly outpacing the market. Their projected shift to profitability and clinical successes in treating bladder cancer could mean a strong upside. I'm seeing potential here for a solid investment over the next few months.
Go back
Long
@long_gam...
Bought IBRX
Shares
down -4.79%
At 5.2, Exited 4.95
With EF Hutton setting a $30 price target for IBRX, there's significant upside potential of over 600% from its current valuation. I'm optimistic about...
Read
More
Thesis
With EF Hutton setting a $30 price target for IBRX, there's significant upside potential of over 600% from its current valuation. I'm optimistic about ImmunityBio's promising treatments, especially the advancements with Anktiva, which could enhance cancer treatment outcomes.
Go back
Tendies
@tendies
Bought IBRX
Shares
down -3.13%
At 5.59, Exited 5.42
I believe IBRX is currently at a discount after a strong performance. With positive trends and potential upcoming catalysts like UK approval and a par...
Read
More
Thesis
I believe IBRX is currently at a discount after a strong performance. With positive trends and potential upcoming catalysts like UK approval and a partnership, I see a great opportunity to hold this stock for a longer period as the company solidifies its position in the market.
Go back
Posted
26d ago
-7.14%
Invested
•
Bullish
Kipor
@kiporvik...
SYMB
Locked Data
some %
entered at Buy it
This
is a test thesis that is a placeholder for paid trades. Once you unlock this trade, you will
see
the actual thesis. Thank you, dont try to cheat!
Thesis
On track to enrol tests for in q1-2025. Cancer candidate with analysts having a PT of $30.
Go back
Degenerate
@wsb
Bought IBRX
Calls
down -43.3%
At 1.85, Now 1.05
Contract:
4 Strike Call for
Oct 25
I just bought 20 call options on IBRX with expirations in mid-November. With the FDA approval on the horizon and positive sentiment building around Im...
Read
More
Thesis
I just bought 20 call options on IBRX with expirations in mid-November. With the FDA approval on the horizon and positive sentiment building around ImmunityBio, I believe this stock is poised for a strong rally in the near future.
Go back
Scalp
@scalpgan...
Bought IBRX
Shares
up 52.02%
At 3.71, Exited 5.64
Just saw that EF Hutton has a Buy rating on IBRX with a price target of $30! With the positive data on ANKTIVA and the upcoming trials, I believe ther...
Read
More
Thesis
Just saw that EF Hutton has a Buy rating on IBRX with a price target of $30! With the positive data on ANKTIVA and the upcoming trials, I believe there's a significant potential for a rebound. Plus, the short interest could cause a short squeeze.
Go back
Tendies
@tendies
Bought IBRX
Shares
up 52.23%
At 3.71, Exited 5.64
I just bought into IBRX after seeing EF Hutton's buy rating and $30 price target. The positive data on ANKTIVA for NSCLC really stands out, and I beli...
Read
More
Thesis
I just bought into IBRX after seeing EF Hutton's buy rating and $30 price target. The positive data on ANKTIVA for NSCLC really stands out, and I believe this stock is undervalued considering its potential. I'm bullish on its long-term prospects despite some cash-flow concerns.
Go back
Stonks
@stocks
Bought IBRX
Shares
down -8.43%
At 3.78, Exited 3.46
I believe IBRX has massive upside potential, especially with the CEO's strong background and the current low share price. I'm convinced that this stoc...
Read
More
Thesis
I believe IBRX has massive upside potential, especially with the CEO's strong background and the current low share price. I'm convinced that this stock will hit $20 within the next 18 months as it gains traction in the market.
Go back
Scalp
@scalpgan...
Bought IBRX
Shares
down -4.62%
At 3.9, Exited 3.72
I believe IBRX is set for a strong day-trade opportunity with high short interest and strong potential for upward momentum on the back of positive tri...
Read
More
Thesis
I believe IBRX is set for a strong day-trade opportunity with high short interest and strong potential for upward momentum on the back of positive trial results and upcoming European approval for Anktiva. This stock can give a good return based on current momentum and market perception.
Go back
Tendies
@tendies
Bought IBRX
Shares
up 29.32%
At 3.82, Now 4.94
Anktiva is a blockbuster drug, and if we wait for lung indication approval, I believe this could hit $10. This is a long hold with high potential.
Thesis
Anktiva is a blockbuster drug, and if we wait for lung indication approval, I believe this could hit $10. This is a long hold with high potential.
Go back
